GSK Agrees to Buy Nuvalent for $10.6 Billion (Video)

GSK, under the leadership of new chief executive Luke Miels, has announced the $10.6 billion acquisition of Nuvalent, a Boston-based cancer treatment firm. This deal represents one of the British drugmaker's largest transactions to date. By acquiring Nuvalent, the FTSE 100 company aims to expand its oncology portfolio, gaining access to two late-stage medications and three drugs specifically developed for lung cancer, significantly enhancing its capabilities in the specialized field of cancer treatment.